Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05680480
Other study ID # 18C030
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 17, 2023
Est. completion date January 2025

Study information

Verified date October 2023
Source RemeGen Co., Ltd.
Contact Binghua Xiao
Phone 86-010-58076833
Email Binghua.xiao@remegen.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.


Description:

This is a phase 2, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of telitacicept versus placebo while taking standard of care (SOC) treatment in adult subjects with active proliferative lupus nephritis (LN).


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date January 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Main Inclusion Criteria: 1. Males or females aged 18-75 years of age, inclusive. 2. Diagnosis of systemic lupus erythematosus according to American College of Rheumatology criteria (1997). 3. Active, biopsy-proven proliferative lupus nephritis Class III or IV with/without the presence of Class V, or pure Class V according to the 2003 ISN/RPS classification. The renal biopsy must be performed within 1 year prior to the screening visit or during screening period. The biopsy report will be used to confirm subject eligibility. 4. Positive serum antibody results, defined as positive anti-nuclear antibody (ANA) and/or a positive anti-dsDNA serum antibody based on the study's central laboratory results. 5. Active renal disease at screening requiring induction therapy with high dose corticosteroids (HDCS) with mycophenolate mofetil (MMF) or other oral forms of mycophenolate. 6. Induction therapy for active renal disease: HDCS with mycophenolate mofetil (MMF) or other oral forms of mycophenolate should be initiated within 60 days prior to or on Day 1 (baseline). Initiation of induction is when both HDCS and MMF have been started. 7. Able to understand the requirements of the study and provide written informed consent. Main Exclusion Criteria: 1. Known hypersensitivity or contraindication to any drug products they plan to receive (e.g., MMF, corticosteroids). 2. History of allergy to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies. 3. Received any of the following therapies: 1. Treatment with any B cell targeted therapy (e.g., rituximab), unless it can be shown that B cells have returned to baseline level or normal; 2. Received tumor necrosis factor inhibitors, interleukin receptor blockers, or other small molecules or biologics (including Belimumab) during the 12 weeks prior to screening or the 5 half-lives of the drug, whichever is longer; 3. Received any experimental drugs during the 12 weeks prior to screening or the 5 half-lives of the drug, whichever is longer; 4. Received plasma separation or plasma exchange during the 6 weeks prior to screening; 5. Subjects who required dialysis within 1 year prior to screening. 6. Received a live vaccine or live-attenuated vaccine within 4 weeks prior to screening or expected to vaccinate during the study. 7. Received BCG Vaccine within 1 year prior to screening. 4. History of severe active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis, or CNS vasculitis) requiring intervention within 60 days of baseline (Day 1). 5. History of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant or are due to receive transplantation. 6. Significant, unstable or uncontrolled acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy, or infectious diseases) which, in the opinion of the principal investigator, could confound the results of the study or put the subject at undue risk. 7. Plan to undergo surgery or have any medical disease, laboratory abnormality, or condition that, in the opinion of the principal investigator, makes the subject unsuitable for the study. 8. History of drug or alcohol abuse or dependence within 364 days prior to baseline (Day 1). 9. Nursing or pregnant female, or male or female who prepared for parenthood during the study. 10. History of malignant tumors within the last 5 years, excluding adequately treated skin cancer (basal or squamous cell) or carcinoma in situ of cervix. 11. Have acute or chronic infection requiring treatment. 12. HIV positive. 13. Hepatitis B: Patients positive for HBsAg are excluded; Patients negative for HBsAg but positive for Anti-HBc, regardless of Anti-HBs antibody status, will require test for HBV DNA: if HBV DNA positive, patients will be excluded; if HBV DNA negative, patients will be eligible to enroll. 14. Hepatitis C antibody positive. 15. History of COVID-19 within 4 weeks prior to screening or history of hospitalization due to severe Covid-19 within 12 months prior to screening. 16. eGFR<30 mL/min/1.73 m2 using CKD-EPI. 17. Renal biopsy showed 50% glomerulosclerosis. 18. Subjects who in the opinion of the investigator are not suitable to participate.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Telitacicept 240 mg
Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.
Telitacicept 160 mg
Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.
Drug:
Placebo
Participants will receive placebo weekly in addition to SOC for 48 weeks.

Locations

Country Name City State
China Affiliated Hospital of Hebei University Baoding Hebei
China The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology Baotou Inner Mongolia
China Peking University People's Hospital Beijing Beijing
China The First Hospital of Jilin University Chang chun Jilin
China The Second Hospital of Jilin University Changchun Jilin
China The Third Xiangya Hospital of Central South University Changsha Hunan
China Xiangya Hospital of Central South University Changsha Hunan
China People's Hospital of Sichuan Province Chengdu Sichuan
China West China Hospital Sichuan University Chengdu Sichuan
China The First Hospital Affiliated to the Army Medical University Chongqing Chongqing
China Guangdong Provincial People's Hospital Guangzhou Guangdong
China The First Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong
China The Third Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong
China Guizhou Provincial People's Hospital Guiyang Guizhou
China Handan First Hospital Handan Hebei
China The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang
China Zhejiang Provincial People's Hospital Hangzhou Zhejiang
China The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) Hefei Anhui
China Qilu Hospital of Shandong University Jinan Shandong
China Taizhou Hospital of Zhejiang Province Linhai Zhejiang
China Liuzhou Workers' Hospital Liuzhou Guangxi
China Jiangxi Provincial People's Hospital Nanchang Jiangxi
China Zhongda Hospital Southeast University Nanjing Jiangsu
China The Affiliated Hospital of Qingdao University Qingdao Shandong
China Huashan Hospital Affiliated to Fudan University Shanghai Shanghai
China Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai Shanghai
China General Hospital of Northern Theater Command of the Chinese People's Liberation Army Shenyang Liaoning
China Shengjing Hospital of China Medical University Shenyang Liaoning
China Hebei General Hospital Shijiazhuang Hebei
China The Third Affiliated Hospital of Hebei Medical University Shijiazhuang Hebei
China Second Hospital of Shanxi Medical University Taiyuan Shanxi
China Shanxi Bethune Hospital Taiyuan Shanxi
China Shanxi Provincial People's Hospital Taiyuan Shanxi
China Tianjin Medical University General Hospital Tianjin Tianjin
China Tianjin Medical University Second Hospital Tianjin Tianjin
China People's Hospital of Xinjiang Uygur Autonomous Region Urumqi Xinjiang
China The First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang
China The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang
China Wuxi People's Hospital Wuxi Jiangsu
China Second Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi
China The First Affiliated Hospital of Xiamen University Xiamen Fujian
China Zhongshan Hospital Affiliated to Xiamen University Xiamen Fujian
China The Affiliated Hospital of Qinghai University Xining Qinghai
China The Fourth Affiliated Hospital, Zhejiang University School of Medicine Yiwu Zhejiang
China The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
RemeGen Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants with Complete Renal Response (CRR) CRR is defined as estimated glomerular filtration rate (GFR) is no more than 20% below the baseline value or = 60 mL/min/1.73m^2 and 24-hour urinary protein: creatinine ratio = 0.5 mg/mg and did not receive prohibited or rescue therapy resulting in treatment failure. Week 48
Secondary Percentage of participants with Partial Renal Response (PRR) PRR is defined as 24-hour urinary protein: creatinine ratio reduced by 50% compared to baseline value. Week 24 and Week 48
Secondary Incidence of AE, SAE An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A SAE is any untoward medical occurrence that at any dose resulting in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant and which the investigator regards as serious based on appropriate medical judgment. Up to Week 48
See also
  Status Clinical Trial Phase
Recruiting NCT02936375 - The Iguratimod Effect on Lupus Nephritis (IGeLU) Phase 2
Completed NCT03597464 - Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin Phase 3
Recruiting NCT01226147 - Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis Phase 2
Completed NCT01206569 - Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Phase 4
Active, not recruiting NCT00569101 - A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis Phase 2
Terminated NCT00368264 - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Phase 2/Phase 3
Completed NCT00371319 - Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Phase 4
Completed NCT00298506 - Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V) N/A
Completed NCT00094380 - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Phase 1/Phase 2
Terminated NCT04376827 - A Study of Guselkumab in Participants With Active Lupus Nephritis Phase 2
Completed NCT03610516 - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis. Phase 2
Recruiting NCT03526042 - Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis N/A
Withdrawn NCT03859570 - Pentoxifylline in Lupus Nephritis Phase 4
Completed NCT03664908 - Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)? N/A
Completed NCT01085097 - A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis Phase 2
Active, not recruiting NCT05704088 - SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients Phase 4
Not yet recruiting NCT06429800 - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis Phase 1
Recruiting NCT02226341 - ACTHar in the Treatment of Lupus Nephritis Phase 4
Recruiting NCT02453997 - Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis N/A
Completed NCT01470183 - Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients N/A